The B-cell lineage restricted receptor CD22, being overexpressed in the majority of B-cell non-Hodgkin lymphomas (B-NHL) [9], as well as in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) [10], is a particularly attractive target for ADC approaches. Here, CD22 is linked to acute lymphoblastic leukemia.